Senesco Acquires More Funding For Possible Myeloma Treatment - On July 29, Senesco Technologies acquired approximately $705,000 from Senesco’s Board of Directors and other investors, including Cato Holding Company, to fund its SNS-01 development program. SNS-01 is a multiple myeloma drug candidate that has shown promising results in mice. Senesco intends to use these funds primarily for multiple myeloma research and for starting a Phase 1 clinical trial in the SNS-01 program. For more information, please see the Senesco Technologies ^[1] press release.

First Connection Training - On August 22 the Leukemia & Lymphoma Society (LLS) is holding an event to provide cancer survivors an opportunity to support current cancer patients in the First Connection Program. This session will teach volunteers the ways to interact with patients who are seeking support, and will feature Janine E. Gauthier, Ph. D., the director of Psychosocial Oncology at Rush University Medical Center. For more information, please visit the LLS ^[2] Website.

For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar ^[3].